Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Oncology · Carcinoma of the Gallbladder and Extrahepatic Biliary Tract

Making Sense of Your Pathology Report and Staging

At a Glance

A gallbladder and bile duct cancer pathology report determines your exact stage and treatment plan. Key details include whether surgical margins are clear of cancer (R0), the exact depth of tumor invasion in millimeters, and whether at least six lymph nodes were evaluated.

A pathology report is the definitive “biography” of your cancer. While it can be filled with dense medical jargon, understanding a few key concepts can help you advocate for the most accurate staging and treatment plan [1][2].

The AJCC 8th Edition: A Major Shift

Doctors use a system called the AJCC (American Joint Committee on Cancer) to stage these diseases. The 8th Edition brought significant changes, specifically moving away from simply looking at which “layers” of the duct wall the cancer has touched [3][4].

Instead, for distal cholangiocarcinoma (dCCA), the system now uses Depth of Invasion (DOI). This is measured in millimeters (mm) [4][5]. This shift happened because the bile ducts are very thin and do not have a distinct muscle layer, making the old “layer-based” staging unreliable [4][6].

The “Six Node Rule” for Gallbladder Cancer

When a surgeon removes a tumor, they also remove nearby lymph nodes to see if the cancer has spread.

  • The Recommendation: Research shows that for gallbladder cancer (GBC), at least 6 lymph nodes should be retrieved and examined [7][8].
  • Why it matters: Sampling fewer than 6 nodes may lead to “understaging,” meaning the cancer might be more advanced than the report suggests [9][10].

Margin Status: R0, R1, and R2

One of the most important sections of your report describes the margins—the edges of the tissue the surgeon removed [1].

  • R0 (Resection 0): No cancer cells were found at the edges under a microscope. This is the goal of every surgery [11][12].
  • R1 (Resection 1): Cancer cells were found at the edges under a microscope, even if they couldn’t be seen by the surgeon’s eye. This often means adjuvant (extra) therapy like chemotherapy or radiation is needed [11][13].
  • R2 (Resection 2): There was visible cancer left behind that the surgeon could see [12].

For Gallbladder Cancer: The “Side” Matters

If you have T2 gallbladder cancer, your report should specify which side of the gallbladder the tumor was on:

  • T2a (Peritoneal side): The tumor is on the side facing away from the liver. This generally has a better prognosis [14][15].
  • T2b (Hepatic side): The tumor is on the side touching the liver. This is associated with a higher risk of the cancer spreading to the liver or lymph nodes and often requires more aggressive surgery [14][16].

Your Pathology Report “Completeness Checklist”

Ensure your report (specifically the synoptic report) includes these essential details:

  1. Histological Grade: Describes how “wild” or aggressive the cells look (Well, Moderately, or Poorly Differentiated) [17][18].
  2. Number of Nodes: Exactly how many lymph nodes were removed and how many were positive for cancer [1][19].
  3. Depth of Invasion (DOI): For bile duct cancers, this should be listed in millimeters [4][5].
  4. Margin Status: Clearly stating R0 or R1 [1].
  5. Cystic Duct Margin: For GBC, it is vital to know if the “exit” of the gallbladder was clear of cancer [20].
  6. Lymphovascular Invasion (LVI): Whether cancer has begun to enter the small blood or lymph vessels [21].

Common questions in this guide

Why is the number of lymph nodes removed important in gallbladder cancer?
During gallbladder cancer surgery, it is recommended that at least six lymph nodes are removed and examined. This ensures accurate staging and prevents the cancer from being mistakenly classified as less advanced than it actually is.
What is the difference between an R0 and R1 margin on my pathology report?
An R0 margin means no cancer cells were found at the edges of the removed tissue, which is the goal of surgery. An R1 margin means microscopic cancer cells were left behind at the edges, which often means extra therapies like chemotherapy or radiation are needed.
How does the location of a T2 gallbladder tumor affect my prognosis?
For T2 gallbladder cancer, the side the tumor is on matters. Tumors on the peritoneal side facing away from the liver generally have a better prognosis. Tumors on the hepatic side touching the liver carry a higher risk of spreading and often require more aggressive surgery.
What does depth of invasion mean for bile duct cancer?
Depth of invasion measures exactly how many millimeters a tumor has grown into the tissue. The current staging system uses this precise measurement for distal cholangiocarcinoma because bile ducts are very thin and lack distinct layers.
What is a synoptic pathology report?
A synoptic report is a structured, checklist version of your pathology report. It is typically more complete than a standard narrative report, making it easier for your care team to quickly find critical details like your histological grade, lymph node count, and margin status.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on the AJCC 8th Edition, what is my specific T, N, and M stage?
  2. 2.For my gallbladder cancer, was the tumor on the hepatic (liver) side or the peritoneal side? How does that affect my risk of recurrence?
  3. 3.My report says [Number] lymph nodes were sampled. Is that enough to be sure we've accurately staged the cancer?
  4. 4.Can you explain the 'Depth of Invasion' (DOI) in my report? Why is it measured in millimeters instead of just by the layer of the duct?
  5. 5.What was the status of my cystic duct margin and my 'R' status (R0 vs R1)?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline.

    Shroff RT, Kennedy EB, Bachini M, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019; (37(12)):1015-1027 doi:10.1200/JCO.18.02178.

    PMID: 30856044
  2. 2

    Current Standards, Multidisciplinary Approaches, and Future Directions in the Management of Extrahepatic Cholangiocarcinoma.

    Wheless M, Agarwal R, Goff L, et al.

    Current treatment options in oncology 2024; (25(1)):127-160 doi:10.1007/s11864-023-01153-5.

    PMID: 38177560
  3. 3

    The 8th Edition American Joint Committee on Cancer Staging for Hepato-pancreato-biliary Cancer: A Review and Update.

    Liao X, Zhang D

    Archives of pathology & laboratory medicine 2021; (145(5)):543-553 doi:10.5858/arpa.2020-0032-RA.

    PMID: 32223559
  4. 4

    Prognostic Relevance of the Eighth Edition of TNM Classification for Resected Perihilar Cholangiocarcinoma.

    Hau HM, Meyer F, Jahn N, et al.

    Journal of clinical medicine 2020; (9(10)) doi:10.3390/jcm9103152.

    PMID: 33003424
  5. 5

    External validation study of the 8th edition of the American Joint Committee on Cancer staging system for perihilar cholangiocarcinoma: a single-center experience in China and proposal for simplification.

    Zhao J, Zhang W, Zhang J, et al.

    Journal of gastrointestinal oncology 2021; (12(2)):806-818 doi:10.21037/jgo-20-348.

    PMID: 34012668
  6. 6

    Survival analysis of patients with stage T2a and T2b perihilar cholangiocarcinoma treated with radical resection.

    Zhao J, Zhang W, Zhang J, et al.

    BMC cancer 2020; (20(1)):849 doi:10.1186/s12885-020-07357-4.

    PMID: 32883228
  7. 7

    Gallbladder Cancer: Imaging Appearance and Pitfalls in Diagnosis.

    John S, Moyana T, Shabana W, et al.

    Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes 2020; (71(4)):448-458 doi:10.1177/0846537120923273.

    PMID: 32412302
  8. 8

    Effect of preoperative jaundice on long-term prognosis of gallbladder carcinoma with radical resection.

    Yang XW, Chen JY, Wen ZJ, et al.

    World journal of surgical oncology 2020; (18(1)):239 doi:10.1186/s12957-020-02015-2.

    PMID: 32891147
  9. 9

    Surgery for gallbladder cancer in the US: a need for greater lymph node clearance.

    Tran TB, Nissen NN

    Journal of gastrointestinal oncology 2015; (6(5)):452-8 doi:10.3978/j.issn.2078-6891.2015.062.

    PMID: 26487937
  10. 10

    Survival Benefits of Simple Versus Extended Cholecystectomy and Lymphadenectomy for Patients With T2 Gallbladder Cancer: A Propensity-Matched Population-Based Study (2010 to 2015).

    Zhang W, Huang Z, Wang WE, Che X

    Frontiers in oncology 2021; (11()):705299 doi:10.3389/fonc.2021.705299.

    PMID: 34513687
  11. 11

    Treatment of Resectable Gallbladder Cancer.

    Vega EA, Mellado S, Salehi O, et al.

    Cancers 2022; (14(6)) doi:10.3390/cancers14061413.

    PMID: 35326566
  12. 12

    Robotic Systematic Portal Lymphadenectomy. Description of Surgical Technique.

    Younos A, Touadi M, Ross S, Sucandy I

    The American surgeon 2023; (89(8)):3603-3604 doi:10.1177/00031348231161079.

    PMID: 36943025
  13. 13

    Gallbladder Cancer: Diagnosis, Surgical Management, and Adjuvant Therapies.

    Hickman L, Contreras C

    The Surgical clinics of North America 2019; (99(2)):337-355 doi:10.1016/j.suc.2018.12.008.

    PMID: 30846038
  14. 14

    The optimal surgical resection approach for T2 gallbladder carcinoma: evaluating the role of surgical extent according to the tumor location.

    Park TJ, Ahn KS, Kim YH, et al.

    Annals of surgical treatment and research 2018; (94(3)):135-141 doi:10.4174/astr.2018.94.3.135.

    PMID: 29520347
  15. 15

    Do hepatic-sided tumors require more extensive resection than peritoneal-sided tumors in patients with T2 gallbladder cancer? Results of a retrospective multicenter study.

    Lee W, Jeong CY, Jang JY, et al.

    Surgery 2017; (162(3)):515-524 doi:10.1016/j.surg.2017.05.004.

    PMID: 28629653
  16. 16

    Lymphatic spread of T2 gallbladder carcinoma: Regional lymphadenectomy is required independent of tumor location.

    Toge K, Sakata J, Hirose Y, et al.

    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2019; (45(8)):1446-1452 doi:10.1016/j.ejso.2019.03.038.

    PMID: 30962045
  17. 17

    [Clinical, epidemiological and therapeutic features of biliary tract cancers: about 20 cases].

    Ka I, Faye M, Diop PS, et al.

    The Pan African medical journal 2018; (29()):13 doi:10.11604/pamj.2018.29.13.9922.

    PMID: 29662598
  18. 18

    Preoperative cachexia index can predict the prognosis of extrahepatic biliary tract cancer after resection.

    Hamura R, Haruki K, Shirai Y, et al.

    Surgical oncology 2022; (44()):101825 doi:10.1016/j.suronc.2022.101825.

    PMID: 35947886
  19. 19

    Validation of the 8th Edition American Joint Commission on Cancer (AJCC) Gallbladder Cancer Staging System: Prognostic Discrimination and Identification of Key Predictive Factors.

    Giannis D, Cerullo M, Moris D, et al.

    Cancers 2021; (13(3)) doi:10.3390/cancers13030547.

    PMID: 33535552
  20. 20

    Positive cystic duct margin at index cholecystectomy in incidental gallbladder cancer is an important negative prognosticator.

    Vega EA, Vinuela E, Sanhueza M, et al.

    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2019; (45(6)):1061-1068 doi:10.1016/j.ejso.2019.01.013.

    PMID: 30704808
  21. 21

    Prognostic predictability of the new American Joint Committee on Cancer 8th staging system for distal bile duct cancer: limited usefulness compared with the 7th staging system.

    Kang JS, Lee S, Son D, et al.

    Journal of hepato-biliary-pancreatic sciences 2018; (25(2)):124-130 doi:10.1002/jhbp.520.

    PMID: 29239127

This page explains gallbladder and bile duct cancer pathology terminology for educational purposes. Your pathologist and oncologist are the best sources for interpreting your specific report.

Get notified when new evidence is published on Carcinoma of gallbladder and extrahepatic biliary tract.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.